Gleolan (5-ALA)
Visualization of malignant tissue during surgery for suspected high-grade gliomas (e.g., glioblastoma)
Key Facts
About NX Development
NX Development Corp is a commercial-stage biotech company specializing in intraoperative imaging for brain tumor resection. Its sole approved product, Gleolan (5-aminolevulinic acid or 5-ALA), received FDA approval in 2017 and is used in fluorescence-guided surgery for high-grade gliomas, allowing surgeons to better distinguish cancerous from healthy tissue. The company's strategy revolves around commercializing this product in the US and exploring further applications of its technology. As a subsidiary of the German firm Photonamic, NX Development leverages its parent company's expertise in fluorescence-based diagnostics while focusing on the US neuro-oncology market.
View full company profile